DACTOLIEVA 0.5MG ( Dactinomycin for Injection USP 0.5MG )

DACTOLIEVA 0.5 mg contains Dactinomycin (Actinomycin D), an antitumor antibiotic. It works by intercalating into DNA, thereby inhibiting RNA synthesis and blocking protein production, leading to cancer cell death. It is especially effective in pediatric and germ cell tumors.

Dactinomycin is indicated for:

1. Wilms’ Tumor (Nephroblastoma)

2. Rhabdomyosarcoma

3. Ewing’s Sarcoma

4. Gestational Trophoblastic Neoplasia / Choriocarcinoma

5. Testicular Cancer (combination regimens)

Common side effects:

•  Severe myelosuppression

•  Nausea, vomiting

•  Mucositis

•  Alopecia

Other side effects:

•  Skin rash

•  Radiation recall dermatitis

Serious side effects:

•  Severe infections

•  Hepatotoxicity

•  Tissue necrosis on extravasation

 Monitor CBC and liver function closely.

Dosage is based on body weight or BSA.

Typical dosing:

•  15 micrograms/kg/day IV for 5 days
    or

•  1.25 mg/m² IV as per protocol

0.5 mg vial allows precise dosing, especially in pediatric patients.

NOTE: This medicine should be taken only under a doctor’s supervision.